---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-014808"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2024-01-25T23:59:59+00:00"
generated_at: "2026-06-06T18:28:51.402613+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics reports positive 72-week Phase 2b atacicept data with eGFR stabilization in IgAN

## Summary
- Atacicept 150mg for 72 weeks: 62% reduction in Gd-IgA1, hematuria to 19%, 48% reduction in UPCR (PP analysis).
- eGFR stable with 0 mL/min/1.73m² change from baseline; placebo-to-atacicept switchers halted eGFR decline (-3.2 vs -4.9 at 36wks).
- Safety consistent with prior trials; generally well-tolerated in OLE.
- Phase 3 ORIGIN 3 enrollment on track for H2 2024; topline data expected H1 2025; BLA submission planned H2 2025.

## SEC filing metadata
- accession: 0001193125-24-014808
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2024-01-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312524014808/0001193125-24-014808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312524014808/d717089d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-014808
- JSON: https://secwatch.observer/filing/0001193125-24-014808.json
- Plain text: https://secwatch.observer/filing/0001193125-24-014808.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.